Background: Hepatotoxic reactions associated with carbamazepine therapy are well recognised, and it is important that clinicians are aware of this adverse effect.
Material and methods: We present the clinical course in three patients with carbamazepine-induced hepatitis.
Results: All three patients had clinical and biochemical signs of hepatitis; improvement occurred immediately after carbamazepine therapy was discontinued. Other causes of hepatitis were excluded.
Interpretation: Previous reports concerning this adverse effect are reviewed. Focusing on the liver as the major organ for drug metabolism, we discuss possible pathophysiological mechanisms of drug-induced hepatic injury. A thorough medication history is mandatory in all patients with hepatitis and other liver diseases. The prognosis of carbamazepine-induced hepatitis is usually excellent, but fatal cases have been reported.